Ramucirumab for the treatment of gastroesophageal cancers

INTRODUCTION: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW. AREAS COVERED: We briefly revi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Expert Opin Orphan Drugs
Main Authors: Shimodaira, Y., Elimova, E., Wadhwa, R., Shiozaki, H., Charalampakis, N., Planjery, V., Rogers, J.E., Song, S., Ajani, J.A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001688/
https://ncbi.nlm.nih.gov/pubmed/27570714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1040390
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados